{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:28:58Z","timestamp":1785781738258,"version":"3.56.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":793,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["20942"],"award-info":[{"award-number":["20942"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1093\/annonc\/mdx410","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T11:17:48Z","timestamp":1501586268000},"page":"2327-2330","source":"Crossref","is-referenced-by-count":17,"title":["\u2018Thursday\u2019s child has far to go\u2019\u2014interpreting subgroups and the STAMPEDE trial"],"prefix":"10.1016","volume":"28","author":[{"given":"M.R.","family":"Spears","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx410_bb0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx410_bb0015","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"Mason","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx410_bb0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx410_bb0025","unstructured":"NHS England. Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone non-metastatic prostate cancer, NHS England, 3019. 2016; (7 July 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx410_bb0030","unstructured":"NICE. Hormone-sensitive metastatic prostate cancer: docetaxel, 2016 Hormone-sensitive metastatic prostate cancer: docetaxel, NICE, 2016 (7 July 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx410_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bmj.39265.596262.AD","article-title":"Subgroup analyses: how to avoid being misled","volume":"335","author":"Fletcher","year":"2007","journal-title":"Br Med J"},{"key":"10.1093\/annonc\/mdx410_bb0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3174\/ajnr.A2442","article-title":"The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms","volume":"32","author":"Naggara","year":"2011","journal-title":"Am J Neuroradiol"},{"key":"10.1093\/annonc\/mdx410_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jama.1991.03470010097038","article-title":"Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials","volume":"266","author":"Yusuf","year":"1991","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdx410_bb0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM198708133170706","article-title":"Statistical problems in the reporting of clinical trials: a survey of three medical journals","volume":"317","author":"Pocock","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx410_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer's guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdx410_bb0060","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","article-title":"Multiplicity in randomised trials. II. Subgroup and interim analyses","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx410_bb0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM197809282991304","article-title":"The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial","volume":"299","author":"Freiman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx410_bb0070","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","article-title":"Forest plots: trying to see the wood and the trees","volume":"322","author":"Lewis","year":"2001","journal-title":"Br Med J"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/10\/2327\/20232798\/mdx410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:08:45Z","timestamp":1624694925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419349658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0923753419349658"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx410","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}